Shoshana Y Kahana1, Maria Isabel Fernandez, Patrick A Wilson, Jose A Bauermeister, Sonia Lee, Craig M Wilson, Lisa B Hightow-Weidman. 1. *Division of Epidemiology, Services, and Prevention Research, National Institute on Drug Abuse/National Institutes of Health, Bethesda, MD; †Department of Preventive Medicine and Department of Public Health Program, College of Osteopathic Medicine, Nova Southeastern University, Ft. Lauderdale, FL; ‡Department of Sociomedical Sciences, Mailman School of Public Health, Columbia University, New York City, NY; §Department of Health Behavior and Health Education, School of Public Health, University of Michigan, Ann Arbor, MI; ‖Maternal Pediatric Infectious Disease Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development/National Institutes of Health, Bethesda, MD; ¶Department of Epidemiology, School of Public Health, University of Alabama at Birmingham, Birmingham, AL; and #Department of Medicine, Division of Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, NC.
Abstract
OBJECTIVE: To measure rates of antiretroviral therapy (ART) use and virologic suppression among perinatally HIV-infected youth (PIY) and behaviorally HIV-infected youth (BIY) linked to care in the United States and examine the effects of demographic, biomedical, and psychosocial factors on those rates. METHODS: Between 2009 and 2012, 649 PIY and 1547 BIY in 20 Adolescent Medicine Trials Network for HIV/AIDS Interventions sites completed cross-sectional surveys through audio computer-assisted self-interviews. Viral load data were collected from chart abstraction or blood draw. RESULTS: Overall 82.4% of PIY and 49.1% of BIY reported current ART use. Only 37.0% of PIY and 27.1% of BIY were virologically suppressed. Virologic suppression rates did not vary as a function of time since HIV diagnosis in either group. Consistent HIV care and no current substance abuse were significant correlates of ART use among PIY. These variables and non-African American race were some factors associated with virologic suppression for PIY [odds ratios (ORs) P < 0.05]. Among BIY, older age, heterosexuals, employment, and education were significantly related to ART use (ORs: P < 0.05); suppression was related to ART use ≥6 months, ≥90% ART adherence, and consistent HIV care (ORs: P < 0.05). Nearly 75% (n = 498) of nonsuppressed youth reported unprotected sex in the past 3 months. CONCLUSIONS: There are continued challenges with successfully treating youth even once diagnosed and linked to HIV care. Strategies targeting barriers to ART access, use, and virologic suppression are needed to optimize the impact of the "Treatment as Prevention" paradigm among PIY and BIY.
OBJECTIVE: To measure rates of antiretroviral therapy (ART) use and virologic suppression among perinatally HIV-infected youth (PIY) and behaviorally HIV-infected youth (BIY) linked to care in the United States and examine the effects of demographic, biomedical, and psychosocial factors on those rates. METHODS: Between 2009 and 2012, 649 PIY and 1547 BIY in 20 Adolescent Medicine Trials Network for HIV/AIDS Interventions sites completed cross-sectional surveys through audio computer-assisted self-interviews. Viral load data were collected from chart abstraction or blood draw. RESULTS: Overall 82.4% of PIY and 49.1% of BIY reported current ART use. Only 37.0% of PIY and 27.1% of BIY were virologically suppressed. Virologic suppression rates did not vary as a function of time since HIV diagnosis in either group. Consistent HIV care and no current substance abuse were significant correlates of ART use among PIY. These variables and non-African American race were some factors associated with virologic suppression for PIY [odds ratios (ORs) P < 0.05]. Among BIY, older age, heterosexuals, employment, and education were significantly related to ART use (ORs: P < 0.05); suppression was related to ART use ≥6 months, ≥90% ART adherence, and consistent HIV care (ORs: P < 0.05). Nearly 75% (n = 498) of nonsuppressed youth reported unprotected sex in the past 3 months. CONCLUSIONS: There are continued challenges with successfully treating youth even once diagnosed and linked to HIV care. Strategies targeting barriers to ART access, use, and virologic suppression are needed to optimize the impact of the "Treatment as Prevention" paradigm among PIY and BIY.
Authors: Allison L Agwu; John A Fleishman; P Todd Korthuis; George K Siberry; Jonathan M Ellen; Aditya H Gaur; Richard Rutstein; Kelly A Gebo Journal: J Acquir Immune Defic Syndr Date: 2011-09-01 Impact factor: 3.731
Authors: Gary Marks; Lytt I Gardner; Jason Craw; Thomas P Giordano; Michael J Mugavero; Jeanne C Keruly; Tracey E Wilson; Lisa R Metsch; Mari-Lynn Drainoni; Faye Malitz Journal: Clin Infect Dis Date: 2011-10-05 Impact factor: 9.079
Authors: Julio S G Montaner; Viviane D Lima; Rolando Barrios; Benita Yip; Evan Wood; Thomas Kerr; Kate Shannon; P Richard Harrigan; Robert S Hogg; Patricia Daly; Perry Kendall Journal: Lancet Date: 2010-07-16 Impact factor: 79.321
Authors: Keri N Althoff; Peter Rebeiro; John T Brooks; Kate Buchacz; Kelly Gebo; Jeffrey Martin; Robert Hogg; Jennifer E Thorne; Marina Klein; M John Gill; Timothy R Sterling; Baligh Yehia; Michael J Silverberg; Heidi Crane; Amy C Justice; Stephen J Gange; Richard Moore; Mari M Kitahata; Michael A Horberg Journal: Clin Infect Dis Date: 2014-01-23 Impact factor: 9.079
Authors: Alexis K Palmer; Angela Cescon; Keith Chan; Curtis Cooper; Janet M Raboud; Caroline L Miller; Ann N Burchell; Marina B Klein; Nima Machouf; Julio S G Montaner; Chris Tsoukas; Robert S Hogg; Mona R Loutfy Journal: J Int Assoc Provid AIDS Care Date: 2013-12-05
Authors: K H Mayer; C O'Cleirigh; M Skeer; C Covahey; E Leidolf; R Vanderwarker; S A Safren Journal: Sex Transm Infect Date: 2009-08-30 Impact factor: 3.519
Authors: Anne M Neilan; Brad Karalius; Kunjal Patel; Russell B Van Dyke; Mark J Abzug; Allison L Agwu; Paige L Williams; Murli Purswani; Deborah Kacanek; James M Oleske; Sandra K Burchett; Andrew Wiznia; Miriam Chernoff; George R Seage; Andrea L Ciaranello Journal: JAMA Pediatr Date: 2017-05-01 Impact factor: 16.193
Authors: Douglas Bruce; Shoshana Y Kahana; Jose A Bauermeister; Sharon L Nichols; Lisa B Hightow-Weidman; Justin E Heinze; Jaclyn Shea; M Isabel Fernández Journal: Drug Alcohol Depend Date: 2015-03-27 Impact factor: 4.492
Authors: Cynthia L Gay; Sarah J Willis; Anna B Cope; JoAnn D Kuruc; Kara S McGee; Joe Sebastian; Amanda M Crooks; Mehri S McKellar; David M Margolis; Susan A Fiscus; Charles B Hicks; Guido Ferrari; Joseph J Eron Journal: AIDS Date: 2016-11-28 Impact factor: 4.177
Authors: Kristi E Gamarel; Larry Brown; Christopher W Kahler; M Isabel Fernandez; Douglas Bruce; Sharon Nichols Journal: Drug Alcohol Depend Date: 2016-10-11 Impact factor: 4.492